Physician Assistant Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Peyton Brouwer

Physician Assistant Roswell, GA Physician Assistant

NPI 1164165353 CMS profile 11398513

1357 Hembree Rd Ste 280, Roswell, GA 30076

Open in the dashboard

General payments

$10,735

450 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Peyton Brouwer of Roswell, GA is reported in the CMS Open Payments database as having received $10,735 across 450 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,420 97
2024 General $3,224 122
2023 General $4,251 208
2022 General $840 23

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Peyton Brouwer
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Peyton Brouwer were reported at $2,420. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Peyton Brouwer Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $0 $132 $37–$438 $132
2022 $840 $155 $48–$522 $149
2023 $4,251 $167 $52–$557 $160
2024 $3,224 $178 $55–$600 $164
2025 $2,420 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. LEO Pharma Inc. $1,871 51 payments
  2. Arcutis Biotherapeutics, Inc. $1,070 45 payments
  3. Dermavant Sciences, Inc. $1,043 27 payments
  4. AbbVie, Inc. $876 39 payments
  5. E.R. Squibb & Sons, L.L.C. $657 36 payments
  6. Genzyme Corporation $639 14 payments
  7. Galderma Laboratories, L.P. $629 13 payments
  8. Amgen Inc. $564 15 payments
  9. Sun Pharmaceutical Industries Inc. $490 29 payments
  10. Ortho Dermatologics, a division of Bausch Health US, LLC $414 38 payments
  11. Other $2,483 143 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $9,955 447 payments
  2. Consulting Fee $675 1 payment
  3. Education $105 2 payments
Products named General payments · program years 2022–2025
  1. ADBRY $1,840 50 payments
  2. VTAMA $1,254 31 payments
  3. Zoryve $861 34 payments
  4. DUPIXENT $729 15 payments
  5. SOTYKTU $657 36 payments
  6. TREMFYA $596 24 payments
  7. Otezla $474 14 payments
  8. Winlevi $411 25 payments
  9. SKYRIZI $404 21 payments
  10. JUBLIA $351 34 payments
  11. Other $3,507 159 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 34 billing codes

Paid by Medicare

$87,128

Medicare's payments for the services billed

Medicare patients

494

Average age 74

Services billed

2,640

282 women, 212 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 67%
Arthritis 40%
Ischemic heart disease 23%
Diabetes 22%
Chronic kidney disease 17%
Atrial fibrillation 15%
Cancer 15%
Depression 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ADBRY
  • LEO Pharma Inc. $580
$580 — —
VTAMA
  • Dermavant Sciences, Inc. $504
$504 — —
Zoryve
  • Arcutis Biotherapeutics, Inc. $432
$432 — —
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $388
$388 — —
Otezla
  • Amgen Inc. $302
$302 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

450 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record